GlassScriptPhysician profile
Carol D Harris
NPI 1710935671
$3,516.48
in general payments reported to CMS, 2019-2025
14 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what 82% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $308 · 2021: $186 · 2022: $93.57 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,155 · Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,155.03 |
| Food and Beverage | $331.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $2,405.85 | 2025 | Iovera |
| Abbott Laboratories | $463.34 | 2019-2022 | |
| Medtronic USA, INC. | $166.84 | 2019-2020 | |
| Daiichi Sankyo INC. | $96.93 | 2019 | |
| Averitas Pharma INC. | $80.30 | 2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $72.59 | 2019 | |
| Nevro Corp. | $54.39 | 2019 | |
| Grt US Holding, INC. | $43.10 | 2021-2022 | |
| Boston Scientific Corporation | $41.79 | 2019-2022 | |
| Redhill Biopharma INC. | $31.77 | 2020 | |
| Biodelivery Sciences International, INC. | $18.61 | 2019 | |
| Pacira Therapeutics, INC. | $14.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.37 | 2019 | |
| Pfizer INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.